Stockreport

AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF AbCellera Biologics Inc. (NASDAQ: ABCL ) is one of the most promising penny stocks under $5 to buy . On February 24, AbCellera Biologics announced its Q4 and full-year [Read more]